Evidence map›Paper›PMID 35637289›Full record

ArticleNature chemistry2022

O-GlcNAcylation modulates liquid-liquid phase separation of SynGAP/PSD-95.

Pinou Lv, Yifei Du, Changdong He, Luxin Peng, Xinyue Zhou, Yi Wan, Menglong Zeng, Wen Zhou, Peng Zou, Chenjian Li and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. O-Glycosylated expansinScience advances · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. O-GlcNAc modulation of nuclear pore complexes orchestrates mRNA export efficiency.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 4 countries.

Pinou Lv *College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Yifei Du *College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Changdong He *State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-5807-6177
Luxin PengCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Xinyue ZhouCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Yi WanCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Menglong ZengDivision of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, China.
Wen ZhouCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China.ORCID http://orcid.org/0000-0003-2639-0687
Peng ZouCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-9798-5242
Chenjian LiPeking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
Mingjie ZhangDivision of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, China.ORCID http://orcid.org/0000-0001-9404-0190
Suwei DongState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China. dongsw@pku.edu.cn.ORCID http://orcid.org/0000-0002-2648-4344
Xing ChenCollege of Chemistry and Molecular Engineering, Peking University, Beijing, China. xingchen@pku.edu.cn.ORCID http://orcid.org/0000-0002-3058-7370
Peking University · CNHong Kong University of Science and Technology · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid-liquid phase separation (LLPS) of SynGAP and PSD-95, two abundant proteins that interact in the postsynaptic density (PSD) of neurons, has been implicated in modulating SynGAP PSD enrichment in excitatory synapses. However, the underlying regulatory mechanisms remain enigmatic. Here we report that O-GlcNAcylation of SynGAP acts as a suppressor of LLPS of the SynGAP/PSD-95 complex. We identified multiple O-GlcNAc modification sites for the endogenous SynGAP isolated from rat brain and the recombinantly expressed protein. Protein semisynthesis was used to generate site-specifically O-GlcNAcylated forms of SynGAP, and in vitro and cell-based LLPS assays demonstrated that T1306 O-GlcNAc of SynGAP blocks the interaction with PSD-95, thus inhibiting LLPS. Furthermore, O-GlcNAcylation suppresses SynGAP/PSD-95 LLPS in a dominant-negative manner, enabling sub-stoichiometric O-GlcNAcylation to exert effective regulation. We also showed that O-GlcNAc-dependent LLPS is reversibly regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). These findings demonstrate that OGT- and OGA-catalysed O-GlcNAc cycling may serve as an LLPS-regulating post-translational modification.

Indexed as

AcetylglucosamineProtein Processing, Post-TranslationalAnimalsNeuronsRatsAcetylglucosamine

Identifiers

PMID35637289
OpenAlexW4281643804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.